Table 12.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1996 to 2005

Recipients with Lung Transplants

  Year of Transplant
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 837 948 893 922 977 1,083 1,054 1,099 1,185 1,407
Tx with Antirejection Treatments 381 421 403 397 432 501 425 356 384 435
Antibodies Any in Category 10.8% 11.6% 15.9% 16.1% 18.8% 11.2% 13.4% 16.0% 13.8% 12.4%
Atgam/NRATG/NRATS 7.3% 7.8% 10.9% 8.1% 7.4% 4.2% 3.1% 4.8% 4.2% 4.1%
OKT3 3.7% 4.3% 3.2% 3.0% 2.5% 1.4% 1.9% 0.8% 1.0% 0.9%
Thymoglobulin 0.0% 0.0% 0.7% 5.0% 5.8% 5.8% 4.9% 5.6% 6.8% 6.9%
Zenapax 0.0% 0.2% 2.2% 1.0% 3.0% 0.8% 5.2% 7.0% 1.8% 0.5%
Simulect 0.0% 0.0% 0.2% 0.8% 2.8% 0.6% 0.2% 0.6% 0.5% 1.1%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.5% 0.6% 0.5% 0.2%
Corticosteroids Any in Category 90.0% 94.1% 91.6% 92.9% 88.2% 92.4% 95.1% 96.3% 93.8% 94.9%
Steroids 90.0% 94.1% 91.6% 92.9% 88.2% 92.4% 95.1% 96.3% 93.8% 94.9%
Antimetabolites Any in Category 5.0% 1.9% 0.7% 1.5% 1.2% 1.2% 0.2% 1.4% 0.5% 1.1%
Cytoxan 0.8% 0.5% 0.2% 0.8% 0.5% 0.2% 0.2% 0.6% 0.5% 0.5%
Methotrexate 4.2% 1.4% 0.5% 1.5% 0.7% 1.0% 0.0% 0.8% 0.0% 0.7%


Source: OPTN/SRTR Data as of May 1, 2007.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.